“…we should bear in mind that “minoritized ethnic and racial groups” are not homogenous but people with very diverse cultural backgrounds within them and with very different histories of success within a country …”
For the fifth instalment of our Diversity, Equity & Inclusion Leadership series, the team recently had an insightful conversation with Dr. Dipti Amin, Director at Maaya Associates Ltd and a Non-Executive Director at Lineage Cell Therapeutics, Buckinghamshire Healthcare NHS Trust, and the University of Hertfordshire. Previously, Chief Compliance Officer at Quintiles Transnational (now IQVIA) Dr Amin brings 29 years’ experience in positions of operational and strategic responsibility within Pharmaceutical Services at the C-suite and Board level.
Coulter Partners partnered recently with Apollo Therapeutics, a portfolio-based biopharmaceutical company rapidly advancing transformative treatments based on breakthrough discoveries, and was pleased to secure the appointment of Dr. Sanjay Aggarwal as the company’s Chief Medical Officer.
Our CEO Bianca Coulter interviews John Dawson, CEO of Oxford Biomedica, who shares up-to-the-minute insights on leadership and innovation in unprecedented times.
Watch the recording in case you missed it.
“Culturally, we have been educated to assume that top leaders must know the best and the most, but inclusion is the opposite, it is making sure that we learn from others.”
For the fourth instalment of our Diversity, Equity & Inclusion Leadership series, the team recently explored D, E & I perspectives from the medtech industry with Guillaume Julien, VP HR Global Sales at Getinge, a leading global provider of medical products and systems, employing more than 10,000 people, with operations in 38 countries.
Coulter Partners was pleased to partner recently with Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, to secure the appointments of three new members to its Board of Directors.
Coulter Partners was pleased to partner recently with Enthera Pharmaceuticals (“Enthera”), a biotech company developing first-in-class biologics for selected autoimmune conditions based on the discovery of a novel apoptosis pathway, to secure the appointment of Antonio Speziale as Chief Medical Officer.
Coulter Partners was pleased to partner recently with MiNA Therapeutics Limited (“MiNA” or the “Company”), the pioneer in small activating RNA (saRNA) therapeutics, to secure the appointments of Troels Koch, Senior Vice President, Chemistry and Ilian Tchakov, Vice President, Clinical Development.
A selection of recent successful placements and new projects globally. Focus in the 3rd quarter of 2021 has been predominantly: Immunology, Oncology, Rare Diseases, Infectious diseases, Neuro-degeneration, A.I. for drug discovery, DNA/ RNA, Vaccines, Drug delivery, Wound care, Telehealth, and Veterinary Services.
Coulter Partners was delighted to partner with Civetta Therapeutics, LLC, a biotechnology company focused on developing a pipeline of therapies that target beta-propeller proteins, to secure the appointment of Christopher D. Roberts, Ph.D., as Chief Executive Officer.
Dr. Roberts, who most recently served as Chief Scientific Officer of Black Diamond Therapeutics, brings more than 20 years of leadership experience discovering and developing novel therapies for oncology, immunology, virology and other indications.
“Good practice means that you have a diverse inclusive board and C-suite, not just token but systematic, and it needs to be beyond just gender and ethnicity. It’s the different ways of thinking that matter.”
For the third instalment of our D&I Leadership series, the team recently had the privilege to spend some time with Dame Kate Bingham, Managing Partner at venture capital firm SV Health Investors, and former Chair of the Government’s Vaccine Taskforce.